Italiano Antoine, Professor of Medicine, Head of Early Phase Trials Unit at Institut Bergonié and Head of Precision Medicine at Gustave Roussy, shared a post on LinkedIn by Zhen Su, CEO at Marengo Therapeutics, adding:
“Honored to present the late-breaking Phase 2 data of Invikafusp alfa at ESMO 2025 on behalf of all the investigators, study teams, and most importantly, our patients.
These results illustrate the potential of harnessing fundamental T-cell biology to bring new options for patients with PD-1–resistant tumors across multiple solid cancers.
Grateful to Marengo Therapeutics for their trust and collaboration, and to all colleagues who made this possible.”
Quoting Zhen Su‘s post:
“We are thrilled to present initial Phase 2 Invikafusp alfa monotherapy clinical data from the STARt-001 trial, showcasing how unlocking fundamental T-cell biology can create new therapeutic options for patients whose tumors no longer respond to PD-1 checkpoint inhibitors.
We extend our heartfelt thanks to the outstanding clinical investigators, study sites, and—most importantly—the patients who placed their trust in this journey.”
More from Zhen Su on OncoDaily.